Key Insights

Highlights

Treatment Research

2 treatments under study, led by Mas825

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Recruiting1
Unknown1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07203001Phase 2RecruitingPrimary

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

NCT01952275Unknown

Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases

Showing all 2 trials

Research Network

Common Treatments

  • Mas8251
  • Collection Of Biological Samples1

Active Sponsors

  • University Of Zurich1
  • Novartis Pharmaceuticals1

Related Conditions

  • Acute Generalized Exanthematous Pustulosis1
  • Infantile Acropustulosis1
  • Rheumatoid Neutrophilic Dermatitis1
  • Pyoderma Gangrenosum1
  • Bowelassociated Dermatosisarthritis Syndrome1

Activity Timeline